RecruitingPhase 2NCT07702292

[68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications

A Phase 2 Study of [68Ga]BED003 for PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications

Sponsor

Blue Earth Diagnostics

Enrollment

65 participants

Start Date

Jun 30, 2026

Study Type

INTERVENTIONAL

Conditions

Colorectal, Cancer Pancreatic Ductal Adenocarcinoma (PDAC)Epithelial Ovarian Cancer Gastric Cancer (GC)Invasive Lobular Breast Carcinoma

Summary

This is a multi-centre, open-label, single-arm, Phase 2 study designed to evaluate the diagnostic performance of \[68Ga\]BED003 in detecting colorectal cancer (CRC), gastric cancer (GC), pancreatic ductal adenocarcinoma (PDAC), invasive lobular breast cancer (ILC), and epithelial ovarian cancer (EOC).

Eligibility

Min Age: 18 YearsMax Age: 79 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called [68Ga]BED003 for people with colorectal, cancer, epithelial ovarian cancer, and other related conditions. The study is currently recruiting participants at 6 locations. People eligible for this study include aged 18 Years to 79 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.